RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation

The RAS-MAPK-pathway is aberrantly regulated in cancer and developmental diseases called RASopathies. While typically the impact of Ras on the proliferation of various cancer cell lines is assessed, it is poorly established how Ras affects cellular differentiation. Here we implement the C2C12 myobla...

Full description

Bibliographic Details
Published in:	European Journal of Cell Biology
Main Authors:	Rohan Chippalkatti, Bianca Parisi, Farah Kouzi, Christina Laurini, Nesrine Ben Fredj, Daniel Kwaku Abankwa
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	Ras Cancer RASopathy Flow cytometry Inhibitors Differentiation
Online Access:	http://www.sciencedirect.com/science/article/pii/S0171933524000426

Similar Items

Editorial: Identifying the isoform-specific roles of RAS paralogs in health and disease
by: Saeideh Nakhaei-Rad, et al.
Published: (2023-04-01)

MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model
by: William E. Tidyman, et al.
Published: (2022-02-01)

Clinical and Cytometric Study of Immune Involvement in a Heterogeneous Cohort of Subjects With RASopathies and mTORopathies
by: Erica Valencic, et al.
Published: (2021-08-01)

Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again
by: Daniel Abankwa, et al.
Published: (2020-11-01)

Updated ACMG/AMP specifications for variant interpretation and gene curations from the ClinGen RASopathy expert panels
by: Emma H. Wilcox, et al.
Published: (2025-01-01)

Editorial: RAS inhibitor therapy of cancer
by: Donald J. Buchsbaum, et al.
Published: (2025-09-01)

RAS‐targeted cancer therapy: Advances in drugging specific mutations
by: Cen Liu, et al.
Published: (2023-06-01)

Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice
by: Rocío Fuentes-Mateos, et al.
Published: (2024-06-01)

Clinical Findings in Children with Noonan Syndrome—A 17-Year Retrospective Study in an Oral Surgery Center
by: Anna Janas-Naze, et al.
Published: (2022-09-01)

A Patient with Noonan Syndrome with a KRAS Mutation Who Presented Severe Nerve Root Hypertrophy
by: Yoshihito Ando, et al.
Published: (2021-02-01)

RASopathies and cardiac manifestations
by: Nazia Hilal, et al.
Published: (2023-07-01)

The RASopathies: from pathogenetics to therapeutics
by: Katie E. Hebron, et al.
Published: (2022-02-01)

RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development
by: Katherine A. Rauen, et al.
Published: (2024-06-01)

Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes
by: Anna Papadopoulou, et al.
Published: (2023-10-01)

Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives
by: Renata Tisi, et al.
Published: (2020-11-01)

Effects of Noonan Syndrome-Germline Mutations on Mitochondria and Energy Metabolism
by: Donald Bajia, et al.
Published: (2022-10-01)

Study of antitumor effectiveness of Ras GTPase peptide inhibitor (Inh-Ras) in xenograft model of non-small cell lung cancer
by: T. M. Kulinich, et al.
Published: (2025-04-01)

Rasopathies case report: concurrence of two pathogenic variations de novo in NF1 and KRAS genes in a patient
by: Irene Baquedano Lobera, et al.
Published: (2019-04-01)

Síndrome de Noonan: actualización genética, clínica y de opciones terapéuticas
by: Atilano Carcavilla, et al.
Published: (2020-07-01)

Editorial: Endocrine aspects of Noonan syndrome and related syndromes
by: Giorgio Radetti, et al.
Published: (2023-01-01)

Ras isoforms: signaling specificities in CD40 pathway
by: Arathi Nair, et al.
Published: (2020-01-01)

Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation
by: Tarah Elizabeth Trebino, et al.
Published: (2023-12-01)

The Ins and Outs of RAS Effector Complexes
by: Christina Kiel, et al.
Published: (2021-02-01)

A flow-cytometry-based pipeline for the rapid quantification of C2C12 cell differentiation
by: Bianca Parisi, et al.
Published: (2023-12-01)

Structure‐energy‐based predictions and network modelling of RASopathy and cancer missense mutations
by: Christina Kiel, et al.
Published: (2014-05-01)

Non-Mammalian Models for Understanding Neurological Defects in RASopathies
by: Mario Rodríguez-Martín, et al.
Published: (2024-04-01)

Molecular inhibition of RAS signalling to target ageing and age-related health
by: Mihails Laskovs, et al.
Published: (2022-10-01)

Anthraquinones as Inhibitors of SOS RAS-GEF Activity
by: Alberto Fernández-Medarde, et al.
Published: (2021-07-01)

n-ras and k-ras Mutations Among Some Iraqi Patients with Acute Lymphoblastic Leukemia
by: Wiaam Ahmed Al-Amili, et al.
Published: (2016-10-01)

RASopathies: Evolving Concepts in Pathogenetics, Clinical Features, and Management
by: Jigna Padhiyar, et al.
Published: (2024-04-01)

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
by: Marta Morante, et al.
Published: (2022-10-01)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
by: Hirofumi Yoshino, et al.
Published: (2023-06-01)

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies
by: Kozo Kataoka, et al.
Published: (2024-04-01)

Detection of Ras nanoclustering-dependent homo-FRET using fluorescence anisotropy measurements
by: Ganesh babu Manoharan, et al.
Published: (2023-06-01)

Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects
by: Maja Solman, et al.
Published: (2022-05-01)

OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
by: L. V. Bolotina
Published: (2015-02-01)

The most important problems and needs of rasopathy patients with a noonan syndrome spectrum disorder
by: Dagmar K. Tiemens, et al.
Published: (2023-07-01)

Everolimus therapy in an infant with Noonan syndrome with multiple lentigines
by: Mani Ram Krishna, et al.
Published: (2025-01-01)

Assessment of the FRET-based Teen sensor to monitor ERK activation changes preceding morphological defects in a RASopathy zebrafish model and phenotypic rescue by MEK inhibitor
by: Giulia Fasano, et al.
Published: (2024-04-01)

Cardiofacio-cutaneous syndrome: Classical presentation of a rare genodermatoses
by: Mahesh Prajapat, et al.
Published: (2016-01-01)